Severe asthma: Can we do better?;Asthme sévère: Comment mieux faire?

Revue des Maladies Respiratoires

Volumn 20, Issue 4, 2003, Pages 495-500

  Chung, K F ^a,c   Blanc, F X ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b BICÊTRE HOSPITAL   (France)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; THEOPHYLLINE;

ASTHMA; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EDITORIAL; PATHOPHYSIOLOGY; PREVALENCE;

ADMINISTRATION, INHALATION; ASTHMA; BRONCHODILATOR AGENTS; DIAGNOSIS, DIFFERENTIAL; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 0141447338     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (37)

1. Chung KF, Godard P: Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13: 1198-208.
2. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2001; 162: 2341-51.
3. Redier H, Daures JP, Michel C, Proudhon H, Vervloet D, Charpin D, Marsac J, Dusser D, Brambilla C, Wallaert B, Godard P: Assessment of the severity of asthma by an expert system. Description and evaluation. Am J Respir Crit Care Med 1995; 151: 345-52.
4. Walsh LJ, Wong CA, Cooper S, Guhan AR, Pringle M, Tattersfield AE: Morbidity from asthma in relation to regular treatment: a community based study. Thorax 1999; 54: 296-300.
5. Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G: Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002; 19: 61-7.
6. Com-Ruelle L, Crestin B, Dumesnil S: L'asthme en France selon les stades de sévérité. CREDES 2000, n° 1290.
7. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH: Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164: 744-8.
8. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C, Thomson NC: Smoking and airway inflammation in patients with mild asthma. Chest 2001; 120: 1917-22.
9. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G: A 15-year follow-up study of ventilatory function in adults with asthma. New Engl J Med 1998; 339: 1194-2000.
10. Chung KF: Difficult, therapy-resistant asthma: definition and clinical features. Monaldi Arch Chest Dis 2000; 55: 459-65.
11. ten Brinke A, Ouwerkerk ME, Zwinderman AH, Spinhoven P, Bel EH: Psychopathology in patients with severe asthma is associated with increased health care utilization. Am J Respir Crit Care Med 2001; 163: 1093-6.
12. Yellowlees PM, Ruffin RE: Psychological defenses and coping styles in patients following a life-threatening attack of asthma. Chest 1989; 95: 1298-303.
13. Sandberg S, Paton JY, Ahola S, McCann DC, McGuinness D, Hillary CR, Oja H: The role of acute and chronic stress in asthma attacks in children. Lancet 2000; 356: 982-7.
14. Bumbacea D, Campbell D, Robinson DS, Chung KF: Significance of persistent airflow obstruction in patients with severe asthma [résumé]. Eur Respir J 2002; 20: 406s.
15. Carr DH, Hibon S, Rubens M, Chung KF: Peripheral airways obstruction on high-resolution computed tomography in chronic severe asthma. Respir Med 1998; 92: 448-53.
16. Stirling RG, Chung KF: Severe asthma: definition and mechanisms. Allergy 2001; 56: 825-40.
17. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW: Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: 1001-8.
18. Kraft M, Cassell GH, Henson JE, Watson H, Williamson J, Marmion BP, Gaydos CA, Martin RJ: Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma Am J Respir Crit Care Med 1998; 158: 998-1001 [erratum in Am J Respir Crit Care Med 1998; 158: 1692].
19. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST: Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003; 111: 215-25.
20. Benayoun L, Druilhe A, Dombret M, Aubier M, Pretolani M: Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167: 1360-8.
21. Paganin F, Trussard V, Seneterre E: Chest radiography and high-resolution computed tomography of the lungs in asthma. Am Rev Respir Dis 1992; 146: 1084-7.
22. Ogirala RG, Aldrich TK, Prezant DJ, Sinnett MJ, Enden JB, Williams MH Jr: High-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma [erratum in New Engl J Med 1991; 324: 1380]. New Engl J Med 1991; 324: 585-9.
23. Stirling RG, Kharitonov SA, Campbell D, Robinson DS, Durham SR, Chung KF, Barnes PJ: Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids. Asthma and Allergy Group. Thorax 1998; 53: 1030-4.
24. Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ: Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532-9.
25. Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A: Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001; 164: 1376-81.
26. Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM: p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109: 649-57.
27. Adcock IM, Chung KF: Overview: why are corticosteroids ineffective in COPD? Curr Opin Investig Drugs 2002; 3: 58-60.
28. Ito K, Caramori G, Oates T, Lim S, Chung KF, Barnes PJ, Adcock IM: Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 106: 392-6.
29. Adcock IM, Stevens DA, Barnes PJ: Interactions of glucocorticoids and beta 2-agonists. Eur Respir J 1996; 9: 160-8.
30. Ayres J, Fish DR, Wheeler DC, Wiggins J, Cochrane GM, Skinner C: Subcutaneous terbutaline and control of brittle asthma or appreciable morning dipping. Br Med J Clin Res Ed 1984; 288: 1715-6.
31. Pauwels RA, Lofdahl C, Postma D, Tattersfield A, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. New Engl J Med 1997; 337: 1405-11.
32. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ: Theophylline plus low dose inhaled steroid is as effective as high dose inhaled steroid in the control of asthma. New Engl J Med 1997; 337: 1412-8.
33. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 2002; 99: 8921-6.
34. Virchow CJ, Prasse A, Naya I, Summerton L, Harris A: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000; 162: 578-85.
35. Robinson DS, Campbell D, Barnes PJ: Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001; 357: 2007-11.
36. Alexander AG, Barnes NC, Kay AB: Cyclosporin A in corticosteroid-dependent chronic severe asthma. Lancet 1992; 339: 324-7.
37. Shiner RJ, Nunn A, Chung KF, Geddes DM: Steroid-sparing effect of methotrexate in the treatment of chronic severe asthma: a double-blind controlled study. Lancet 1990; 336: 137-40.